scispace - formally typeset
Patent

Bioerodible silicon-based compositions for delivery of therapeutic agents

Christian Barnett, +2 more
Reads0
Chats0
TLDR
In this paper, a bioerodible porous silicon-based carrier material is proposed for treating or preventing conditions of a patient such as chronic diseases, where the carrier material carries at least one large molecule therapeutic agent and amorphous sugar, optionally further comprising a crystallization inhibitor.
Abstract: 
The invention comprises a composition comprising a bioerodible porous silicon-based carrier material wherein the carrier material carries at least one large molecule therapeutic agent and at least one amorphous sugar, optionally further comprising a crystallization inhibitor. The composition may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The composition may be used for treating or preventing conditions of a patient such as chronic diseases.

read more

Citations
More filters
Patent

Particles comprising subparticles or nucleic acid scaffolds

Louis Hawthorne, +1 more
TL;DR: In this paper, a number of compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof, have been disclosed, including compositions that specifically bind a target, such as a biomolecule on the surface of a pathogen, to inhibit the target from interacting with other molecules or cells.
Patent

Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension

Schiffman Rhett M, +1 more
TL;DR: In this paper, a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, an Tie-2 agonist, a NATRIuretic peptide Receptor-B (NPR-B) compound or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (fASL) inhibitor, including any combination of these compounds and a sustained delivery component is described.
Patent

Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (fas) or fas ligand (fasl) inhibitor, a tumor necrosis factor-alpha (tnf-alpha) or tnf receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitor

Schiffman Rhett M, +1 more
TL;DR: In this article, a drug delivery system comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand inhibitor, a tumor necrosis factor-α (TNF-α) or TNF receptor (TNFR) inhibitor, including any combination of these compounds and, optionally, a sustained delivery component is described.
References
More filters
Journal ArticleDOI

Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers

Igor I. Slowing, +3 more
- 17 Aug 2008 - 
TL;DR: This review highlights the recent research developments of a series of surface-functionalized mesoporous silica nanoparticle (MSN) materials as efficient drug delivery carriers and envision that these MSN-based systems have a great potential for a variety of drug delivery applications.
Journal ArticleDOI

Porous silicon in drug delivery devices and materials

Emily Anglin, +3 more
- 17 Aug 2008 - 
TL;DR: The optical properties of photonic structures prepared from porous Si or SiO2 hosts provide a self-reporting feature that can be monitored in vivo.
Patent

Microchip drug delivery devices

John T. Santini, +3 more
TL;DR: In the field of microfabrication, an active device can be controlled by a preprogrammed microprocessor, remote control, or by biosensors as mentioned in this paper, where the physical properties of the release system control the rate of release of the molecules.
Journal ArticleDOI

The biocompatibility of porous silicon in tissues of the eye.

Suet P. Low, +3 more
- 01 May 2009 - 
TL;DR: A porous silicon membrane may have value as a biomaterial that can support the delivery of cells to the ocular surface and improve existing therapeutic options in patients with corneal epithelial stem cell dysfunction and ocularsurface disease.
Patent

Methods and apparatus for delivery of ocular implants

David A. Weber, +5 more
TL;DR: In this paper, a simple manual depression of an actuator produces proportional movement of a linkage causing the implant or microimplant to be ejected through a cannula disposed at the desired location in the eye.